Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a letter under SEBI Regulation 30 to stock exchanges informing them that the Q4/FY26 earnings conference call was conducted and providing a link to the audio recording hosted on the company’s website. It does not contain financial results or the full call transcript itself, nor is it the initial earnings highlights. It is a regulatory announcement about publishing an earnings call recording, falling under general regulatory filings.
2026-06-01 English
Earning Call Recording- For the Quarter and financial year ended on March 31, 2026
Regulatory Filings Classification · 85% confidence The document is a stock exchange filing under SEBI Listing Regulations informing regulators that the earnings call recording for Q4 FY26 has been hosted on the company’s website. It contains no financial data, no transcript, and is not a full earnings release—merely an announcement to the exchange. It does not present the call transcript or company results. As such, it falls under a general regulatory announcement (Regulatory Filings) rather than CT, ER, RPA, or other specific categories.
2026-06-01 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed slide deck titled “Investor’s Presentation” submitted under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30, containing narrative commentary, charts, and full financial statements (P&L, balance sheet, cash flow) for Q4 and FY26. It is clearly an investor presentation rather than a regulatory announcement or press release of results. Therefore, it best fits the “Investor Presentation” category (Code: IP).
2026-05-30 English
Pursuant to Regulation 30 and Schedule III part A of SEBI Listing Regulations, Investor Presentation on audited Standalone and Consolidated Financial Results for the quarter and financial ....
Investor Presentation Classification · 96% confidence The document is titled “Investor’s Presentation on audited Standalone and Consolidated Financial Results for the Quarter and financial year ended on March 31, 2026” and consists of slide decks with financial highlights, charts, commentary and full P&L, balance sheet and cash flow extracts. It is submitted under SEBI LODR Regulation 30 as an investor presentation package. This matches the definition of detailed presentations for investors focusing on financials, strategy, and market position.
2026-05-30 English
Copy of Newspaper Publication
Earnings Release Classification · 84% confidence The document is a press release filed with Indian stock exchanges under SEBI Listing Regulations announcing audited standalone and consolidated financial results for the quarter and full financial year ended March 31, 2026. It contains tables of actual financial results (income, net profit, etc.) and is the company’s initial announcement of its periodic earnings performance rather than a full annual report or proxy document. This matches the definition of an Earnings Release (ER). FY 2026
2026-05-30 English
Extracts of newspaper publications dated May 30, 2026 of the audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2026.
Interim / Quarterly Report Classification · 85% confidence The document is a statutory disclosure by Concord Biotech Limited under SEBI (Listing Obligations and Disclosure Requirements) Regulations. It is titled “Press Release – For the quarter and financial year ended on March 31, 2026” and encloses extracts of the audited Standalone and Consolidated Financial Results for the quarter and full year. It includes actual financial data tables, not merely a certification or link to a report. This aligns with an Interim/Quarterly Report category, as it presents substantive financial statements for a period shorter than a full fiscal year (quarter end) plus the year‐end extracts. Therefore, the correct classification is IR (Interim / Quarterly Report). FY 2026
2026-05-30 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.